SCHEMBL4718689

SCHEMBL4718689

Brc1ccc(Nc2cccc3cnccc23)nc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ROCK1 Q13464 2/20 0.48
CHEK1 O14757 1/20 0.48
PIM1 P11309 1/20 0.48
CDK8 P49336 1/20 0.48
GSK3B P49841 1/20 0.48
CDK7 P50613 1/20 0.48
CDK9 P50750 1/20 0.48
LIMK1 P53667 1/20 0.48
CLK4 Q9HAZ1 1/20 0.48
TRPV1 Q8NER1 3/20 0.47
CCR4 P51679 1/20 0.45
ROCK2 O75116 2/20 0.45
MAPT P10636 7/20 0.44
LMNA P02545 4/20 0.44
KMT2A Q03164 4/20 0.44
MEN1 O00255 3/20 0.44
ALDH1A1 P00352 6/20 0.42
KDM4E B2RXH2 5/20 0.42
SMN1; SMN2 Q16637 3/20 0.42
CYP1A2 P05177 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4717837 0.76 TRPV1 (0.64) TRPV1MAPTALDH1A1KDM4ESMN1; SMN2
SCHEMBL6832925 0.74 ADRA2A (0.50) ROCK1CHEK1PIM1CDK8GSK3B
SCHEMBL25175478 0.73 ADRA2A (0.70) ROCK1TRPV1CCR4ROCK2MAPT
SCHEMBL15452589 0.72 CDK2 (0.50) ROCK1TRPV1CCR4ROCK2MAPT
SCHEMBL4717951 0.72 ALDH1A1 (0.45) ROCK1TRPV1CCR4ROCK2MAPT
SCHEMBL4717939 0.71 MAPK10 (0.50) ROCK1TRPV1CCR4ROCK2MAPT
SCHEMBL355054 0.70 ALDH1A1 (0.50) CDK9CLK4MAPTLMNAKMT2A
SCHEMBL1735616 0.70 ROCK2 (0.55) ROCK1CCR4ROCK2MAPTLMNA
SCHEMBL31629163 0.70 LMNA (0.58) ROCK1TRPV1CCR4ROCK2MAPT
SCHEMBL2477664 0.70 LMNA (0.58) ROCK1TRPV1CCR4ROCK2MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7442701-B2 Amino-heterocycles as VR-1 antagonists for treating pain MERCK SHARP & DOHME LTD. (GB) 2008-10-28 US disclosed
EP-1562934-B1 AMINO-HETEROCYCLES AS VR-1 ANTAGONISTS FOR TREATING PAIN MERCK SHARP & DOHME (GB) 2008-03-26 EP disclosed
US-20060040947-A1 Amino-heterocycles as vr-1 antagonists for treating pain MERCK SHARP & DOHME LTD. (GB) 2006-02-23 US disclosed
EP-1562934-A1 AMINO-HETEROCYCLES AS VR-1 ANTAGONISTS FOR TREATING PAIN MERCK SHARP & DOHME LTD. (GB) 2005-08-17 EP disclosed
WO-2004046133-A1 AMINO-HETEROCYCLES AS VR-1 ANTAGONISTS FOR TREATING PAIN MERCK SHARP & DOHME LIMITED (GB) 2004-06-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060040947-A1 Amino-heterocycles as vr-1 antagonists for treating pain OPRL1, CNR1, GPR6 ROCK1 4271/4885CHEK1 2354/4885PIM1 3496/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.